Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

Core Viewpoint - Appili Therapeutics Inc. has submitted four new funding proposals totaling US$117.5 million to advance treatments for infectious diseases, aligning with public health priorities [1] Funding Opportunities - The company applied for two solicitations from the National Institute of Allergy and Infectious Diseases (NIAID), seeking US$46.3 million for a vaccine against invasive fungal infections and US$36.4 million for an antifungal monoclonal antibody targeting a rare fungal infection [2] - Additionally, two proposals were submitted to the US Medical CBRN Defense Consortium (MCDC) for a total of US$34.8 million, including US$20.1 million for a broad-spectrum treatment for viral infections and US$14.7 million for a direct-acting antiviral [3] Consortium Membership - Appili has been selected to join the MCDC, which has awarded over US$7 billion in project funding, enhancing the company's role in developing medical countermeasures [4] Previous Funding Success - The company has raised approximately US$33.2 million in prior government funding awards, which have supported the development of various pipeline programs, including ATI-1701 and LIKMEZ™ [6] Update on USAFA Awards - Appili received an update regarding its arrangement with the United States Air Force Academy (USAFA) for ATI-1701, with a total of approximately US$14 million awarded, of which US$11.6 million has been allocated for services [7][10] - A modification to the USAFA Cooperative Agreement has resulted in an increased General & Administrative overhead recovery rate, benefiting the company financially [8] Going-Private Transaction - The company is in the process of a going-private transaction with Aditxt Inc., which has received shareholder and court approvals, with an extended deadline for financing set to March 31, 2025 [11][12][13]